the first TNFi used, we conditionally recommend treatment with secukinumab or ixekizumab over treatment with a different TNFi in patients with primary nonresponse to TNFi (new, In adults with active AS despite treatment with the first TNFi used, we conditionally recommend treatment with a different TNFi over treatment with a non-TNFi biologic in patients with secondary nonresponse to TNFi (new, In adults with active AS despite treatment with the first TNFi used, we strongly recommend against